New Year Bumper Sale @ Rs. 1 X
Starcad T 25 Tablet ER is a commercial drug that is prescribed in the form of Tablet. Starcad T 25 Tablet ER also has some secondary and off-label uses. These are listed below.
The correct dosage of Starcad T 25 Tablet ER depends on the patient's age, gender, and medical history. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. This information has been provided in detail in the dosage section.
Common side effects of Starcad T 25 Tablet ER include Headache, Dizziness, Weakness. Besides the aforementioned side effects, there are other adverse effects of Starcad T 25 Tablet ER as well, which are listed below. Usually, these side effects of Starcad T 25 Tablet ER go away soon, and do not persist beyond the duration of the treatment. If, however, they worsen or do not go away, please speak with your physician.
It is also important to note that Starcad T 25 Tablet ER has a Severe effect for pregnant women and Safe effect on lactating mothers. It is important to know if Starcad T 25 Tablet ER has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Starcad T 25 Tablet ER related warnings section.
Starcad T 25 Tablet ER is not recommended if you suffer from certain medical conditions as it can have adverse effects. Diabetes, Congestive Heart Failure (CHF), Angioedema are examples of such conditions.
Drug interactions for Starcad T 25 Tablet ER have been reported in the medical literature. A complete list of these interactions is given below.
In addition to these precautions, you may also note that Starcad T 25 Tablet ER is not safe while driving, and is is not addictive in nature.
Starcad T 25 Tablet ER is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
Adult |
|
Geriatric |
|
Is the use of Starcad T 25 Tablet ER safe for pregnant women?
Pregnant women may get severe side effects after taking Starcad T. If you are pregnant, do not take Starcad T without a doctor's advice.
Is the use of Starcad T 25 Tablet ER safe during breastfeeding?
Starcad T is safe for breastfeeding women.
What is the effect of Starcad T 25 Tablet ER on the Kidneys?
Kidney can be affected by Starcad T. If you experience any unwanted effects of this drug, stop taking it. You should take it again only after medical advice.
What is the effect of Starcad T 25 Tablet ER on the Liver?
The liver can be affected by Starcad T. If you experience any unwanted effects of this drug, stop taking it and consult your doctor. You should restart Starcad T only after medical advice.
What is the effect of Starcad T 25 Tablet ER on the Heart?
Starcad T has very mild side effects on the heart.
Starcad T 25 Tablet ER should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Starcad T 25 Tablet ER unless your doctor advises you to do so -
Is this Starcad T 25 Tablet ER habit forming or addictive?
Starcad T 25 Tablet ER is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
After taking Starcad T 25 Tablet ER you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
Yes, but consume Starcad T 25 Tablet ER only on doctor's advice.
Is it able to treat mental disorders?
No, Starcad T 25 Tablet ER is not used to treat mental disorders.
Interaction between Food and Starcad T 25 Tablet ER
There isn't any research available on the side effects of taking Starcad T 25 Tablet ER with food.
Interaction between Alcohol and Starcad T 25 Tablet ER
Due to lack of research, nothing can be said about side effects of consuming alcohol while taking Starcad T 25 Tablet ER.
Starcad T can be taken as long as it is prescribed by your doctor. You must not discontinue taking it even when you start feeling well. In addition, you must not take it more frequently as that can have adverse effects. Follow the recommendations of your doctor completely.
No, Starcad T is not a beta blocker/calcium channel blocker/diuretic/blood thinner/ace inhibitor. It is angiotensin II receptor blocker (an antihypertensive drug).
Yes, Starcad T causes hyponatremia (low level of sodium in the blood). Treatment with telmisartan might call for a regular blood monitoring for checking sodium levels.
No, Starcad T does not cause weight gain. Weight gain has rarely been associated with this drug. However, if you are experiencing unusual weight gain and you are in doubt that Starcad T is causing weight gain then discuss with your doctor instantly.
Yes, Starcad T may cause a cough on rare occasions. If you experience a cough while taking Starcad T, please talk to your doctor immediately.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 169-173
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 507
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Micardis® (telmisartan)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Twynsta® (telmisartan/amlodipine)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lopressor (metoprolol tartrate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 148-149
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 847-850